Discover strategies that can help patients with Primary Periodic Paralysis (PPP) better manage their attacks.
Primary Periodic Paralysis (PPP) is a complex genetic disorder, but it can be managed with a straightforward approach focused on:
PPP can progress to Permanent Muscle Weakness (PMW) — constant weakness that can occur independently of attacks and becomes more likely in the fifth and sixth decades of life.1,2
As a provider, you’re in a unique position to improve your patient’s PPP by helping to guide them through the following approaches.
“Frequent attacks can have a substantial impact on a patient’s ability to work and perform daily activities, so it makes sense to do whatever possible to minimize the frequency and severity of attacks.”
Certain medications can help patients both prevent and manage PPP episodes.
In addition to long-term medication, helping your patient identify and manage their triggers is crucial to reducing them. Common triggers include3,6:
Take potassium supplements as recommended by a healthcare provider.6,7 Eat a low sodium, low carbohydrate diet.
Eat frequent carbohydrate-heavy meals.6,7 Avoid potassium-rich foods.
Attacks of muscle stiffness that occur during activity such as exercise.9
Avoid cold temperatures and strenuous exercise.7
Light exercise may help decrease the severity of an episode.8
Since 2016, we’ve been helping patients with PPP identify and manage their triggers and reduce PPP attacks with KEVEYIS. Through
Xeris CareConnection™, get access to a treatment support program specifically for patients with PPP and their providers.
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Concomitant Use of Aspirin or Other Salicylates
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.
The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.
Please see Full Prescribing Information.
Keveyis®, Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc.
By submitting this form, I understand I am giving Xeris Pharmaceuticals, Inc., its affiliates, and business partners permission to use the personal information provided in this registration form to contact me by the following methods, but not limited to: mail, email, telephone call or in-person about disease and product information, disease or product-related events, support services, market research, and to share promotional and marketing information. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Xeris Pharmaceuticals® Terms of Use and Privacy Statement. I understand I can unsubscribe by clicking on the unsubscribe link in future communications or by sending a letter with my full contact information (eg, name, address, email, phone, etc) to Xeris CareConnection™ Patient Support Services, 1375 W Fulton Street, Suite 1300, Chicago, IL 60607.
